Preoperative robotic radiosurgery for early breast cancer: Results of the phase II ROCK trial (NCT03520894).
Breast cancer
Partial breast irradiation
Preoperative radiotherapy
Robotic radiosurgery
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
16
09
2022
accepted:
18
09
2022
entrez:
30
9
2022
pubmed:
1
10
2022
medline:
1
10
2022
Statut:
epublish
Résumé
Preoperative partial breast irradiation (PBI) has got the advantage of treating a well-defined target. We report the results of the phase II ROCK trial (NCT03520894), enrolling early breast cancer (BC) patients treated with preoperative robotic radiosurgery (prRS), in terms of acute and early late toxicity, disease control, and cosmesis. The study recruited between 2018 and 2021 at our Radiation Oncology Unit. Eligible patients were 50 + years old BC, hormonal receptors positive/human epidermal growth factor receptor 2 negative (HR+/HER2-), sized up to 25 mm. The study aimed to prospectively assess the toxicity and feasibility of a robotic single 21 Gy-fraction prRS in preoperative setting. A total of 70 patients were recruited and 22 patients were successfully treated with pRS. Overall, three G1 adverse events (13.6 %) were recorded within 7 days from prRS. Three events (13.6 %) were recorded between 7 and 30 days, one G2 breast oedema and two G1 breast pain. No acute toxicity greater than G2 was recorded. Five patients experienced early late G1 toxicity. One patient reported G2 breast induration. No early late toxicity greater than G2 was observed. At a median follow up of 18 months (range 6-29.8), cosmetic results were scored excellent/good and fair in 14 and 5 patients, respectively, while 3 patients experienced a poor cosmetic outcome. ROCK trial showed that a single 21 Gy dose prRS represents a feasible technique for selected patients affected by early BC, showing an acceptable preliminary toxicity profile.
Sections du résumé
Background and purpose
UNASSIGNED
Preoperative partial breast irradiation (PBI) has got the advantage of treating a well-defined target. We report the results of the phase II ROCK trial (NCT03520894), enrolling early breast cancer (BC) patients treated with preoperative robotic radiosurgery (prRS), in terms of acute and early late toxicity, disease control, and cosmesis.
Material and methods
UNASSIGNED
The study recruited between 2018 and 2021 at our Radiation Oncology Unit. Eligible patients were 50 + years old BC, hormonal receptors positive/human epidermal growth factor receptor 2 negative (HR+/HER2-), sized up to 25 mm. The study aimed to prospectively assess the toxicity and feasibility of a robotic single 21 Gy-fraction prRS in preoperative setting.
Results
UNASSIGNED
A total of 70 patients were recruited and 22 patients were successfully treated with pRS. Overall, three G1 adverse events (13.6 %) were recorded within 7 days from prRS. Three events (13.6 %) were recorded between 7 and 30 days, one G2 breast oedema and two G1 breast pain. No acute toxicity greater than G2 was recorded. Five patients experienced early late G1 toxicity. One patient reported G2 breast induration. No early late toxicity greater than G2 was observed. At a median follow up of 18 months (range 6-29.8), cosmetic results were scored excellent/good and fair in 14 and 5 patients, respectively, while 3 patients experienced a poor cosmetic outcome.
Conclusions
UNASSIGNED
ROCK trial showed that a single 21 Gy dose prRS represents a feasible technique for selected patients affected by early BC, showing an acceptable preliminary toxicity profile.
Identifiants
pubmed: 36177053
doi: 10.1016/j.ctro.2022.09.004
pii: S2405-6308(22)00079-9
pmc: PMC9513617
doi:
Types de publication
Journal Article
Langues
eng
Pagination
94-100Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Icro Meattini reports occasional speaker honoraria supported by Eli Lilly, Novartis, Pfizer, Accuray, and Seagen, outside the submitted work. No other competing interests declared.
Références
Lancet Oncol. 2021 May;22(5):597-608
pubmed: 33845035
Int J Radiat Oncol Biol Phys. 2020 Apr 1;106(5):958-967
pubmed: 31987957
Int J Radiat Oncol Biol Phys. 2020 Jan 1;106(1):174-181
pubmed: 31525407
Ann Surg Oncol. 2012 Oct;19(10):3275-81
pubmed: 22851048
Radiother Oncol. 2010 Mar;94(3):292-9
pubmed: 19963294
Semin Radiat Oncol. 2008 Oct;18(4):215-22
pubmed: 18725106
Eur J Cancer. 2017 Sep;82:184-192
pubmed: 28692950
Radiother Oncol. 2010 Mar;94(3):264-73
pubmed: 20181402
J Clin Oncol. 2020 Dec 10;38(35):4175-4183
pubmed: 32840419
Front Oncol. 2011 Nov 21;1:43
pubmed: 22649764
BJU Int. 2020 Mar;125(3):417-425
pubmed: 31608534
Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):846-55
pubmed: 26104938
Am J Clin Oncol. 1993 Jun;16(3):223-8
pubmed: 8338056
Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1193-9
pubmed: 23332384
N Engl J Med. 2002 Oct 17;347(16):1227-32
pubmed: 12393819
Lancet. 2016 Jan 16;387(10015):229-38
pubmed: 26494415
Crit Rev Oncol Hematol. 2019 Sep;141:102-111
pubmed: 31272045
Lancet Oncol. 2022 Jan;23(1):e21-e31
pubmed: 34973228
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6
pubmed: 7713792
N Engl J Med. 2002 Oct 17;347(16):1233-41
pubmed: 12393820
Oncologist. 2016 Feb;21(2):131-3
pubmed: 26764248
Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1393-404
pubmed: 15590170
Breast. 2007 Oct;16(5):456-61
pubmed: 17606373
Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1325-1331
pubmed: 33333201
Phys Med. 2020 Mar;71:31-38
pubmed: 32088563
Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):747-753
pubmed: 28244410
Radiother Oncol. 2021 Sep;162:185-194
pubmed: 34302915
J Clin Oncol. 1996 May;14(5):1558-64
pubmed: 8622072
Strahlenther Onkol. 2017 Apr;193(4):324-331
pubmed: 28124093
Breast. 2004 Dec;13(6):452-60
pubmed: 15563851
Int J Radiat Oncol Biol Phys. 2020 Mar 15;106(4):821-829
pubmed: 31812720
Lancet. 2017 Sep 9;390(10099):1048-1060
pubmed: 28779963
J Clin Oncol. 1999 Aug;17(8):2326-33
pubmed: 10561294